how to define limit for mutagenic impurity in drug product
Published 3 years ago • 9.5K plays • Length 17:04Download video MP4
Download video MP3
Similar videos
-
26:07
how to define limit for unknown, known and total impurities
-
28:15
acceptable intakes for mutagenic impurities in relation to ltl exposure
-
17:16
how to define limit for newly identified nitrosamine impurity?
-
15:03
how to decide impurities in api & drug products and their release and shelf life specification
-
12:37
which limits apply for nitrosamines in medicinal products?
-
11:31
calculation of an unknown impurity in the combination drug product
-
10:21
is the less than lifetime (ltl) limit applies to nitrosamines?
-
6:15
control of impurities in pharmaceuticals
-
9:24
how to calculate limit for nitrosamines in ppm as per usfda guideline
-
21:43
how to define limit for residual solvents in drug product
-
5:42
what is meant by genotoxicity & mutagenicity?
-
10:43
how to decide the concentration for the sample and standard in related substances?
-
8:35
how to decide the need of testing nitrosamine impurities into pharmaceuticals?
-
6:29
why the ai for ndma is 96ng/day?
-
22:27
how to determine detection limit (lod) and quantitation limit (loq)
-
11:47
how to derive an ai for new n-nitrosamine?
-
19:36
why does ich recommend only specificity and lod for the validation of impurity by limit test?
-
23:11
why i don't agree to some of the stability storage conditions?
-
![[multidisciplinary] ich m7 addendum](https://i.ytimg.com/vi/XKnx0PRevpI/mqdefault.jpg)
43:24
[multidisciplinary] ich m7 addendum